| Description |
1 online resource (293 pages) |
| Series |
Frontiers in Anti-Infective Drug Discovery Ser. ; v. 7 |
|
Frontiers in Anti-Infective Drug Discovery Ser
|
| Contents |
880-01 Intro; CONTENTS; PREFACE; List of Contributors; The Role of the Microbiota in the Genesis of Gastrointestinal Cancers; Edda Russo and Amedeo Amedei*; 1. INTRODUCTION; 2. THE HUMAN MICROBIOTA; 3. THE GASTROINTESTINAL MICROBIOTA; 3.1. Composition and Activities; 3.2. Gastro-Intestinal Colonization by the Microbiota and Selection; 3.3. The Human Microbiome Project; 3.4. Gut Enterotypes; 4. THE ROLE OF MICROBIOTA IN TUMOR DEVELOPMENT; 4.1. Proposed Models for Microbiota-induced Carcinogenesis; 4.2. Antibacteria-Specific Immune Response and Cancer Promotion; 5. MICROBIOTA AND GI CANCERS |
|
880-01/(S PROTEIN PROCESSINGEndoplasmic Reticulum α-glucosidases; Furin; Endoplasmic Reticulum Associated Signal Peptidase; INNATE ANTIVIRAL RESPONSE; Interferon Activity; Cell-intrinsic Restriction Factors; CONCLUDING REMARKS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Synergistic Interaction Between Plant Products and Antibiotics Against Potential Pathogenic Bacteria; Banasri Hazra1,*, Sutapa Biswas Majee2, Subhalakshmi Ghosh1 and Dhruti Avlani2; INTRODUCTION; BACTERIAL RESISTANCE TOWARDS CLINICAL ANTIBIOTICS; Background; Mechanisms and Associated Factors |
|
5.1. Gut Bacteria Dysbiosis Associated with GI Cancer5.2. Microbiota Involvement in Gastric and Esophageal Cancers, the Role of Helicobacter pylori; 5.3. Microbiota Involvement in Colorectal Cancer; 5.3.1. Specific Gut Bacteria and CRC; 5.3.2. Bacteria Metabolites and CRC; 5.4. Gallbladder Cancer; 5.5. Liver Cancer; 5.6. Pancreatic Cancer; 6. BENEFICIAL ACTIVITIES OF GUT MICROBIOTA; 6.1. Antitumorigenic Impact of Microbiota; 6.2. Manipulating the Microbiota for Cancer Therapy; 7. CONCLUSION; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES |
|
Towards Host Cell-Targeting Therapies to Treat Dengue Virus InfectionsCybele C. García1,2, Verónica M. Quintana1, Viviana Castilla1 and Elsa B. Damonte1,2,*; INTRODUCTION; INTERACTION WITH CELL RECEPTORS; ENDOCYTOSIS AND FUSION FOR UNCOATING; LIPID METABOLISM; PROTEIN TRANSLATION; UNFOLDED PROTEIN RESPONSE; UBIQUITIN PROTEASOME PATHWAY; NUCLEOTIDE METABOLISM; KINASES; Mitogen-activated Protein Kinases; ERK Pathway; JNK Pathway; p38 Pathway; Other Kinases; Src, Ab1 and Fyn Kinases; AP2-associated Protein Kinase 1 and Cyclin G-associated Kinase; Phosphatidylinositol 3 Kinase/Akt Pathway |
|
SCREENING STRATEGIES TO CHARACTERISE PLANT PRODUCTS WITH POTENTIAL RESISTANCE MODIFYING ACTIVITYASSESSMENT OF SYNERGISTIC INTERACTION BETWEEN ANTIBIOTIC AND A PHYTOCOMPOUND AGAINST RESISTANT BACTERIA; Fractional Inhibitory Concentration Index (FICI); Modulation Factor (MF); Isobologram; SEARCH FOR PLANT-DERIVED SECONDARY METABOLITES WITH PROSPECTIVE RESISTANCE MODIFYING ACTIVITY; Key Early Studies Pertaining to Discovery of RMAs from Plants; Recent Studies; PHYTOCHEMICALS AND RELEVANT BACTERIAL RESISTANCE MECHANISMS; Efflux Pump Inhibition; Alteration of Bacterial Cell Membrane Permeability |
| Notes |
Protein Synthesis Inhibition |
|
Print version record |
| Subject |
Anti-infective agents.
|
|
Communicable diseases.
|
|
Anti-Infective Agents
|
|
Communicable Diseases
|
|
Anti-infective agents
|
|
Communicable diseases
|
| Form |
Electronic book
|
| Author |
Chaudhry, Iqbal
|
| ISBN |
9781681085623 |
|
1681085623 |
|
